Drug industry technology company Kalderos, which has struggled to launch its 340B Pay service to let drug companies provide 340B pricing as a post-purchase rebate instead of as an up-front discount, has replaced its chief executive officer.
Drug industry technology company Kalderos, which has struggled to launch its 340B Pay service to let drug companies provide 340B pricing as a post-purchase rebate instead of as an up-front discount, has replaced its chief executive officer.
*Sign up for news summaries and alerts from 340B Report